Chronic myeloid leukaemia

8 trials 4 recruiting MedDRA PT
8 Registered trials
4 Recruiting
5 Unique sponsors
5 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 5
Mechanism of action (INN-stem analysis)
Kinase inhibitor 5 substances
Phase III: 1 Phase II: 5 Phase I/II: 1 Phase IV: 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

1 trial
  • Novartis Pharma AG Commercial
    NILOTINIB
    2023-507557-16-00 14 countries 2022 n=260
    Recruiting

Phase II

5 trials
  • Novartis Pharma AG Commercial
    ASCIMINIB HYDROCHLORIDE
    2025-522138-29-00 6 countries n=14 Orphan
    Pending
  • Fondazione Gimema Franco Mandelli Onlus Academic
    ASCIMINIB HYDROCHLORIDE; NILOTINIB
    2024-512696-12-00 2 countries 2025 n=160 Orphan
    Recruiting
  • Friedrich-Schiller-Universitaet Jena Academic
    IMP not specified
    2024-516212-24-00 1 country 2024 n=125
    Ended
  • Friedrich-Schiller-Universitaet Jena Academic
    IMP not specified
    2024-516214-38-00 1 country 2024 n=10
    Ended
  • Region Uppsala Academic
    DASATINIB
    2024-515409-25-00 3 countries 2018 n=32
    Recruiting

Phase I/II

1 trial
  • Incyte Corp. Commercial
    PONATINIB
    2023-509699-41-00 6 countries 2019 n=57 Orphan
    Recruiting

Phase IV

1 trial
  • Fondazione Gimema Franco Mandelli Onlus Academic
    IMATINIB; NILOTINIB
    2023-510434-83-00 2 countries 2016 n=450
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase II, Phase III 1
Fondazione Gimema Franco Mandelli Onlus Academic 2 Phase II, Phase IV 1
Friedrich-Schiller-Universitaet Jena Academic 2 Phase II 0
Incyte Corp. Commercial 1 Phase I/II 1
Region Uppsala Academic 1 Phase II 1
New trials by year
2019
1
2022
1
2024
2
2025
1
← All indication landscapes